[go: up one dir, main page]

AU2002210415A1 - Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor - Google Patents

Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor

Info

Publication number
AU2002210415A1
AU2002210415A1 AU2002210415A AU1041502A AU2002210415A1 AU 2002210415 A1 AU2002210415 A1 AU 2002210415A1 AU 2002210415 A AU2002210415 A AU 2002210415A AU 1041502 A AU1041502 A AU 1041502A AU 2002210415 A1 AU2002210415 A1 AU 2002210415A1
Authority
AU
Australia
Prior art keywords
inhibitor
egfr antagonist
aromatase
antitumor combination
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002210415A
Inventor
Giorgio Massimini
Giovanni Minardi
Gabriella Piscitelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of AU2002210415A1 publication Critical patent/AU2002210415A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002210415A 2000-07-18 2001-07-04 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor Abandoned AU2002210415A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0017635.4 2000-07-18
GBGB0017635.4A GB0017635D0 (en) 2000-07-18 2000-07-18 Antitumor combined therapy
PCT/EP2001/007676 WO2002005791A2 (en) 2000-07-18 2001-07-04 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor

Publications (1)

Publication Number Publication Date
AU2002210415A1 true AU2002210415A1 (en) 2002-01-30

Family

ID=9895895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002210415A Abandoned AU2002210415A1 (en) 2000-07-18 2001-07-04 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor

Country Status (6)

Country Link
US (1) US20050032759A1 (en)
EP (1) EP1315486A2 (en)
JP (1) JP2004503582A (en)
AU (1) AU2002210415A1 (en)
GB (1) GB0017635D0 (en)
WO (1) WO2002005791A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363627A2 (en) 2001-02-19 2003-11-26 Novartis AG Treatment of solid tumours with rapamycin derivatives
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
DE602004004553T2 (en) 2003-09-19 2007-10-25 Astrazeneca Ab quinazoline derivatives
BRPI0415395A (en) * 2003-10-15 2006-12-12 Osi Pharm Inc compound, methods for inhibiting protein kinase activity and treating a patient who has a condition that is mediated by protein kinase activity, and,
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
EP2305682A1 (en) 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP1751309B1 (en) * 2004-05-27 2015-07-22 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
CA2567852A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US20060148772A1 (en) * 2004-11-16 2006-07-06 Evans Astrid H Combination
BRPI0518104B8 (en) 2005-01-21 2021-05-25 Genentech Inc industrialized article and use of her2 antibody
RU2404806C2 (en) 2005-02-23 2010-11-27 Дженентек, Инк. Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
US7704129B2 (en) * 2005-07-12 2010-04-27 Tipper Tie, Inc. Ruckers capable of rucking fixed diameter coverings and associated devices, methods, systems and computer program products
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd ANTICANCER PHARMACEUTICAL COMPOSITION
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2700986A1 (en) 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
JP2011510018A (en) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド Imidazopyrazinol derivatives for cancer treatment
CL2009000647A1 (en) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
WO2009138780A2 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Therapeutic treatment - 355
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
EP2408817B1 (en) 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Bispecific anti-her antibodies
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
JP2012526138A (en) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー Use of OSI-906 to treat adrenocortical cancer
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
CN102068429B (en) * 2010-12-28 2011-12-14 西南大学 Application of fadrozole in inducing transformation of differentiated ovary of tilapia mossambica into functional testis and induction method thereof
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CN104220457A (en) 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 Diagnosis and treatment involving HER3 inhibitors
EP3511718A1 (en) 2012-11-30 2019-07-17 F. Hoffmann-La Roche AG Pd-l1 inhibitor
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
USD729294S1 (en) 2013-08-26 2015-05-12 Tipper Tie, Inc. Gripper for automated ruckers, reruckers, deruckers and/or skin brakes
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN1729002A (en) * 2000-09-08 2006-02-01 法玛西雅意大利公司 Exemestane as Chemopreventive Agent

Also Published As

Publication number Publication date
WO2002005791A2 (en) 2002-01-24
GB0017635D0 (en) 2000-09-06
JP2004503582A (en) 2004-02-05
WO2002005791A3 (en) 2003-01-03
US20050032759A1 (en) 2005-02-10
EP1315486A2 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
AU2002210415A1 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2002358277A1 (en) Aerogel and metallic compositions
AU2001258771A1 (en) -secretase inhibitors
AU2002356762A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
SI1251848T1 (en) Gyrase inhibitors and uses thereof
AU2002255284A1 (en) Quinoline derivative having azolyl group and quinazoline derivative
AU2001240978A1 (en) Glycogen phosphorylase inhibitor
AU2002367773A1 (en) Fab i inhibitors
AU2001244302A1 (en) Assessment methods and systems
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
AU2002320156A1 (en) Risk evaluation system and methods
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2002338989A1 (en) Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine derivatives
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
AU6045801A (en) Inhibitor function check method and apparatus
AU2002354083A1 (en) Cylinder-lock and flat-key combination
WO2003020115A9 (en) Methods and compositions for the detection of cancer
AU2002259301A1 (en) Caspase inhibitors and uses thereof
HK1063733A (en) Caspase inhibitors and uses thereof
AU2002223649A1 (en) Vegh inhibitors and their use
AU2002332460A1 (en) Pyrazole-derived kinase inhibitors and uses thereof
AU2002305259A1 (en) Triazole-derived kinase inhibitors and uses thereof